Skip to main content
Top
Gepubliceerd in: Huisarts en wetenschap 5/2005

01-05-2005 | Ingezonden

NHG-Standaard Hartfalen

Auteur:    

Gepubliceerd in: Huisarts en wetenschap | Uitgave 5/2005

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

NHG- Standaarden zijn goed bruikbaar in de zorg en in nascholing. Gelukkig is de NHG-Standaard Hartfalen herzien (H&W 2005;48:64-76), maar op een aantal punten ben ik het niet eens met de inhoud.
Literatuur
go back to reference Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. for the CHARM investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet 2003;362:772-6.CrossRef Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. for the CHARM investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet 2003;362:772-6.CrossRef
go back to reference Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355(9215):1582-7.CrossRefPubMed Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355(9215):1582-7.CrossRefPubMed
go back to reference Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360(9335):752-60.CrossRefPubMed Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360(9335):752-60.CrossRefPubMed
go back to reference Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN; Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40(8):1414-21.CrossRefPubMed Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN; Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40(8):1414-21.CrossRefPubMed
go back to reference Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002;39:463-70.CrossRefPubMed Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002;39:463-70.CrossRefPubMed
go back to reference Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.CrossRefPubMed Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.CrossRefPubMed
go back to reference Fuchs SA, Meyboom RHB, Van Puijenbroek EP, Guchelaar H-J. Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema. Pharm World Sci 2004;26:191-2.CrossRefPubMed Fuchs SA, Meyboom RHB, Van Puijenbroek EP, Guchelaar H-J. Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema. Pharm World Sci 2004;26:191-2.CrossRefPubMed
Metagegevens
Titel
NHG-Standaard Hartfalen
Auteur
   
Publicatiedatum
01-05-2005
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Huisarts en wetenschap / Uitgave 5/2005
Print ISSN: 0018-7070
Elektronisch ISSN: 1876-5912
DOI
https://doi.org/10.1007/BF03084422

Andere artikelen Uitgave 5/2005

Huisarts en wetenschap 5/2005 Naar de uitgave

Boeken

Van slag